Share

October 05, 2021; 97 (14) Editorial

People With Myasthenia Are Getting Better, but Are They Doing Well?

Chloë Atkins, Carolina Barnett
First published August 10, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012617
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
144

Share

Article Information

vol. 97 no. 14 663-664
DOI: 
https://doi.org/10.1212/WNL.0000000000012617
PubMed: 
34376510
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published August 10, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Chloë Atkins, PhD and
    2. Carolina Barnett, MD, PhD
  1. Chloë Atkins, PhD and
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. My Imaginary Illness: A Journey into Uncertainty and Prejudice in Medical Diagnosis; Cornell University Press 2010.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Social Sciences and Humanities Research Council and Department of National Defense Research (Canada) joint initiative. - Insight grant 2019-2023)Social Sciences and Humanities Research Council - Connections grant 2021University of Toronto Global Teaching Grant 2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. TechNation 2020,2021Catherine and Fredrik Eaton Family Charitable Foundation 2021-2024

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Carolina Barnett, MD, PhD
    3. Scientific Advisory Boards:

    1. Canadian Advisory board for Alexion.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Alexion (2)Akcea (3) Takeda (4) CSL (5) Sanofi

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Research grant from Octapharma, for clinician-initiated research (2) research grant from Grfiols for clinician-initiated research

    Research Support, Government Entities:

    1. (1) US Department of Defense. Neurofibromatosis program, new investigator award. Role: PI, year: 2019-2022 (2) NIH. PAR-17-184. Role: Co-investigator. 2018-2023

    Research Support, Academic Entities:

    1. (1) New initiatives grant. University of Toronto, Division of Neurology

    Research Support, Foundations and Societies:

    1. (1) Muscular Dystrophy Canada. Seed Grant. Role; co-investigator. 2019-2020 (2) Muscular Dystrophy Canada. Health management grant. PI. 2020- 2022 (3) MG Net

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) May receive future royalties for licensing of the MGII

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the PROUD Project on Employment and Disability (C.A.), Department of Political Science, Scarborough College, and Institute of Health Policy, Management and Evaluation (C.B.), Dalla Lana School of Public Health, University of Toronto; Living With MG for 30+ Years (EOMG, Diagnostic Delay) (C.A.); and Ellen and Martin Prosseman Centre for Neuromuscular Disease (C.B.), University Health Network, Toronto, Ontario, Canada.
  1. Correspondence
    Dr. Barnett c.barnetttapia{at}utoronto.ca
View Full Text

Article usage

Article usage: August 2021 to February 2023

AbstractFullPdfSource
Aug 2021009Highwire
Sep 2021033Highwire
Oct 20215077032Highwire
Nov 202115737Highwire
Dec 2021115413Highwire
Jan 2022125716Highwire
Feb 20229036Highwire
Mar 20226614Highwire
Apr 20224446Highwire
May 20224412Highwire
Jun 20226268Highwire
Jul 20226914Highwire
Aug 20225514Highwire
Sep 20226938Highwire
Oct 20224412Highwire
Nov 202289214Highwire
Dec 20224501Highwire
Jan 20232512Highwire
Feb 20232523Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me